| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| T Svoboda, A Luger, E Knosp, G Geye. [Treatment of prolactinoma with a new dopamine agonist]. Deutsche medizinische Wochenschrift (1946). vol 116. issue 33. 1991-09-20. PMID:1678695. |
eleven patients (6 men, 5 women, mean age 42 [25-65] years) with prolactinomas were treated for 4-16 months with a new dopamine agonist (cv 205-502), at a daily dose of between 0.075 and 0.45 mg. all patients had previously undergone surgery and/or been treated with bromocriptine or lisuride, but had not tolerated this therapy well, and/or had not shown sufficient suppression of serum prolactin levels. |
1991-09-20 |
2023-08-11 |
Not clear |
| T Svoboda, A Luger, E Knosp, G Geye. [Treatment of prolactinoma with a new dopamine agonist]. Deutsche medizinische Wochenschrift (1946). vol 116. issue 33. 1991-09-20. PMID:1678695. |
the new dopamine agonist is an alternative treatment for prolactinomas where other therapies have been unsuccessful. |
1991-09-20 |
2023-08-11 |
Not clear |
| G Fagli. Should dopamine agonist treatment for prolactinomas be life-long? Clinical endocrinology. vol 34. issue 3. 1991-06-28. PMID:1674680. |
should dopamine agonist treatment for prolactinomas be life-long? |
1991-06-28 |
2023-08-11 |
Not clear |
| L Duranteau, P Chanson, A Lavoinne, S Horlait, J Lubetzki, J M Kuh. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clinical endocrinology. vol 34. issue 1. 1991-04-25. PMID:1672268. |
we compared the long-term effects of bromocriptine and cv 205-502 (a non-ergot derivative d2 dopamine agonist) on plasma prolactin levels and tumour size in seven bromocriptine-resistant prolactinomas. |
1991-04-25 |
2023-08-11 |
Not clear |
| J Ton. [Reaction of human pituitary prolactinoma cells to TRH and dopamine in vitro]. Zhonghua yi xue za zhi. vol 70. issue 11. 1991-04-09. PMID:1963362. |
[reaction of human pituitary prolactinoma cells to trh and dopamine in vitro]. |
1991-04-09 |
2023-08-11 |
human |
| R A Burgett, P A Garris, N Ben-Jonatha. Estradiol-induced prolactinomas: differential effects on dopamine in posterior pituitary and median eminence. Brain research. vol 531. issue 1-2. 1991-04-01. PMID:2289118. |
estradiol-induced prolactinomas: differential effects on dopamine in posterior pituitary and median eminence. |
1991-04-01 |
2023-08-11 |
rat |
| J R Davi. Prolactin and related peptides in pregnancy. Bailliere's clinical endocrinology and metabolism. vol 4. issue 2. 1991-01-04. PMID:2248596. |
enlargement of pre-existing prolactinomas may occur during pregnancy induced with dopamine agonist drugs, and this can be a major clinical problem with larger tumours. |
1991-01-04 |
2023-08-11 |
Not clear |
| P S Barnett, J M Dawson, J Butler, P B Coskeran, J J Maccabe, A M McGrego. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. Clinical endocrinology. vol 33. issue 2. 1990-12-05. PMID:1977537. |
cv205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. |
1990-12-05 |
2023-08-11 |
Not clear |
| J R Davis, M C Sheppard, D A Heat. Giant invasive prolactinoma: a case report and review of nine further cases. The Quarterly journal of medicine. vol 74. issue 275. 1990-09-20. PMID:2385731. |
in vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mrna, suggesting relative autonomy of prolactin synthesis. |
1990-09-20 |
2023-08-11 |
Not clear |
| M el-Azouzi, D W Hsu, P M Black, F Jolesz, E T Hedley-Whyte, A Klibanski, N T Zerva. The importance of dopamine in the pathogenesis of experimental prolactinomas. Journal of neurosurgery. vol 72. issue 2. 1990-02-21. PMID:1967303. |
the importance of dopamine in the pathogenesis of experimental prolactinomas. |
1990-02-21 |
2023-08-11 |
rat |
| M el-Azouzi, D W Hsu, P M Black, F Jolesz, E T Hedley-Whyte, A Klibanski, N T Zerva. The importance of dopamine in the pathogenesis of experimental prolactinomas. Journal of neurosurgery. vol 72. issue 2. 1990-02-21. PMID:1967303. |
one hypothesis, that chronic loss of dopamine control from the hypothalamus may be associated with prolactinoma formation, was tested. |
1990-02-21 |
2023-08-11 |
rat |
| R J Ross, J M McEniery, A Grossman, I Doniach, G M Besser, M O Savag. Massive prolactinoma with galactorrhoea in a prepubertal boy. Postgraduate medical journal. vol 65. issue 764. 1990-02-12. PMID:2608583. |
the management of massive prolactinomas is difficult, but the child presented has made an impressive response to a combination of treatment with surgery, dopamine agonist therapy and radiotherapy. |
1990-02-12 |
2023-08-11 |
Not clear |
| J S Bevan, C W Burk. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH. Clinical endocrinology. vol 30. issue 6. 1990-01-17. PMID:2512041. |
during perifusion with dopamine (da, 5 mumol/l) untreated prolactinomas had a higher prl secretion rate (19.3 +/- 2.7 microu/mg tissue/min, mean +/- sem) than bc-treated (3.9 +/- 0.7, p = 0.005). |
1990-01-17 |
2023-08-11 |
human |
| M Le Dafniet, J Blumberg-Tick, H Gozlan, A Barret, D Joubert Bression, F Peillo. Altered balance between thyrotropin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries. The Journal of clinical endocrinology and metabolism. vol 69. issue 2. 1989-08-28. PMID:2502552. |
altered balance between thyrotropin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries. |
1989-08-28 |
2023-08-11 |
Not clear |
| M Le Dafniet, J Blumberg-Tick, H Gozlan, A Barret, D Joubert Bression, F Peillo. Altered balance between thyrotropin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries. The Journal of clinical endocrinology and metabolism. vol 69. issue 2. 1989-08-28. PMID:2502552. |
we measured trh and dopamine (da) concentrations in prolactinomas and other pituitary tumors in order to further understand the roles of these two factors in the hormone hypersecretion and growth of these tumors. |
1989-08-28 |
2023-08-11 |
Not clear |
| I Pellegrini, R Costa, F Grisoli, P Jaque. Abnormal dopamine sensitivity in some human prolactinomas. Hormone research. vol 31. issue 1-2. 1989-07-11. PMID:2722137. |
abnormal dopamine sensitivity in some human prolactinomas. |
1989-07-11 |
2023-08-11 |
human |
| K Mikawa, M Kusunoki, H Obara, S Iwa. Effect of dopamine on plasma growth hormone and prolactin concentrations under anaesthesia. The Journal of international medical research. vol 16. issue 6. 1989-05-11. PMID:3234595. |
concentrations of plasma growth hormone in patients with acromegaly and concentrations of plasma prolactin in patients with prolactinoma were measured before anaesthesia, when 250 mg levodopa was administered orally, and after anaesthesia when dopamine was infused intravenously at a rate of 5 micrograms/kg.min. |
1989-05-11 |
2023-08-11 |
Not clear |
| M F el Etreby, B Lorenz, U F Habenich. Immunocytochemical studies on the pituitary gland and spontaneous pituitary tumors of Sprague-Dawley rats. Pathology, research and practice. vol 183. issue 5. 1989-05-03. PMID:3070515. |
the review of our studies indicates a predictive value of the pituitary gland and spontaneous pituitary tumors of sprague-dawley rats for detecting and evaluating the effects and interactions of estrogens and dopamine agonists on the pathogenesis, functional morphology and therapy of human pituitary tumors, such as prolactinomas, gonadotroph adenomas and null cell adenomas. |
1989-05-03 |
2023-08-11 |
human |
| J H Mattox, J Bernstein, M T Buckma. Control of hyperprolactinemia with pergolide. International journal of fertility. vol 30. issue 4. 1988-01-19. PMID:2890594. |
ten patients with clinical, laboratory and radiographic evidence compatible with the diagnosis of prolactinoma were treated with two dopamine agonists. |
1988-01-19 |
2023-08-11 |
Not clear |
| R A Prysor-Jones, J J Silverlight, J S Jenkins, B J Merr. Vasoactive intestinal polypeptide and dopamine in the hypothalamus and pituitary of ageing rats with prolactinomas. Acta endocrinologica. vol 116. issue 1. 1987-11-10. PMID:3661055. |
vasoactive intestinal polypeptide and dopamine in the hypothalamus and pituitary of ageing rats with prolactinomas. |
1987-11-10 |
2023-08-11 |
rat |